NR4A3 Antibody (monoclonal) (M06)
Mouse monoclonal antibody raised against a partial recombinant NR4A3.
|Application ||WB, IF, E|
|Calculated MW||68230 Da|
|Other Names||Nuclear receptor subfamily 4 group A member 3, Mitogen-induced nuclear orphan receptor, Neuron-derived orphan receptor 1, Nuclear hormone receptor NOR-1, NR4A3, CHN, CSMF, MINOR, NOR1, TEC|
|Target/Specificity||NR4A3 (NP_008912, 414 a.a. ~ 521 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||NR4A3 Antibody (monoclonal) (M06) is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a member of the steroid-thyroid hormone-retinoid receptor superfamily. The encoded protein may act as a transcriptional activator. The protein can efficiently bind the NGFI-B Response Element (NBRE). Three different versions of extraskeletal myxoid chondrosarcomas (EMCs) are the result of reciprocal translocations between this gene and other genes. The translocation breakpoints are associated with Nuclear Receptor Subfamily 4, Group A, Member 3 (on chromosome 9) and either Ewing Sarcome Breakpoint Region 1 (on chromosome 22), RNA Polymerase II, TATA Box-Binding Protein-Associated Factor, 68-KD (on chromosome 17), or Transcription factor 12 (on chromosome 15). Multiple transcript variants encoding different isoforms have been found for this gene.
1.Over-expression of Neuron-derived Orphan Receptor-1 (NOR-1) exacerbates neointimal hyperplasia after vascular injury.Rodriguez-Calvo R, Guadall A, Calvayrac O, Navarro MA, Alonso J, Ferran B, de Diego A, Muniesa P, Osada J, Rodriguez C, Martinez-Gonzalez JHum Mol Genet. 2013 Feb 13.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.